Thromboprophylaxis with low-molecular-weight heparin: Economic considerations

Haemostasis

Volumn 30, Issue SUPPL. 2, 2000, Pages 141-145

  Mätzsch, Thomas ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cost effectiveness; Low molecular weight heparin; Postoperative thromboembolism; Thromboprophylaxis

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; ECONOMIC ASPECT; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HUMAN; META ANALYSIS; ORTHOPEDIC SURGERY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; THROMBOSIS PREVENTION;

EID: 0034461644     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054181     Document Type: Conference Paper

References (19)

1. The prevalence of risk factors for venous thromboembolism among hospital patients
2. Clinical course and incidence of post-thrombotic syndrome after profound asymptomatic deep vein thrombosis. Results of a transverse epidemiologic study
3. Cost of long-term complications of deep venous thrombosis of the lower extremities: An analysis of a defined patient population in Sweden
4. Thromboprophylaxis with low molecular weight heparin after major orthopedic surgery is cost effective
5. Prevention of venous thromboembolism
6. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery
7. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement
8. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective
9. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery
10. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis
11. Low molecular weight heparin in prevention of perioperative thrombosis
12. Cost effectiveness of the prevention and treatment of deep vein thrombosis and pulmonary embolism
13. Economic analysis of low-dose heparin versus the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery
14. Thromboembolic prophylaxis in moderate-risk patients undergoing elective abdominal surgery: Decision and cost-effectiveness analyses
15. Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty
16. Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement
17. Cost-effectiveness of prophylactic anticoagulation prolonged after hospital discharge following general surgery
18. Formulary management of low molecular weight heparins
19. Principles of pharmacoeconomic analysis of drug therapy